ACRS Aclaris Therapeutics has 3 clinical trials releasing topline data this year and sufficient cash to fund their operations through the end of 2025. ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023. ACRS reached 52 week low today: $5.05. Analysts Price Targets: $21 The Goldman Sachs Group $29 BTIG Research $38 Cantor Fitzgerald $43 HC...
Expecting a move down to create what sort of resembles an inverted H&S lacking the left shoulder If you look at the overall pattern its evident its in a down channel A touch on the diagonal dotted line would be good.
IMO Aclaris Therapeutics Inc. stock can go up to $16.55 and I am bullish on it. My trade levels are: Entry level: $14.05 Take profit: $16.55 Stop loss: $13.45 Risk/reward: 4.17
NASDAQ:ACRS Possible Scenario: LONG Evidence: Price Action TP1: ~7 TP2: ~7.60 This is my idea and could be wrong 100%
Very risky, they are presenting data.